Primary aldosteronism (PA) is caused by autonomous secretion of aldosterone from the adrenal cortex. PA accounts for \~10% of secondary hypertension in adults, and 30% to 80% of the adult-onset PA is due to aldosterone-producing adenoma (APA) \[[@B1]\]. The Japan Endocrine Society guidelines for the diagnosis and treatment of PA recommend measurement of plasma renin activity and plasma or serum aldosterone concentration (PAC) in all patients initially diagnosed with hypertension \[[@B2]\]. However, PA is not a major cause of secondary hypertension in children \[[@B3]\]. Only 23 children younger than age 15 years with APA have been previously reported. The clinical characteristics of pediatric-onset APA remain elusive.

In 2011, somatic *KCNJ5* mutations were identified in adult-onset APA \[[@B4]\]. The somatic *KCNJ5* mutations of adult-onset APA was detected in 43% (range, 12% to 80%) with ethnic variation \[[@B5]\]. However, pediatric-onset APA in patients in whom a somatic *KCNJ5* mutation was confirmed has not been reported.

We report an 11-year-old Japanese girl with APA with a somatic *KCNJ5* mutation and review the clinical presentations of previously reported cases of pediatric-onset APA and familial hyperaldosteronism (FH) type III carrying germline *KCNJ5* mutations.

1. Case Report {#s1}
==============

An 11-year-old girl was referred to us for hypertension and hypokalemia. She was diagnosed with "cyclic vomiting" on the basis of recurrent headaches and nausea for more than 2 years. There was no family history of hypertension or any other symptoms associated with hypokalemia. Her height and weight were 154.4 cm (75th to 90th percentile) and 41.5 kg (25th to 50th percentile), respectively. Her blood pressure was 149/105 mm Hg (95th percentile for age, 126/82 mm Hg), and her heart rate was 92 beats/min. Her serum potassium was 2.7 mEq/L. Venous blood pH and HCO~3~^−^ were 7.437 and 29.5 mEq/L, respectively, indicating metabolic alkalosis. Her plasma renin activity was \<0.1 ng/mL per hour (reference range, 0.6 to 7.5 ng/mL per hour), and her PAC was 28.6 ng/dL (reference range, 0.2 to 20 ng/dL). Plasma ACTH and serum cortisol levels were 16.5 pg/mL and 16.7 µg/dL, respectively. These findings were consistent with PA, and further tests, including captopril-challenge, upright furosemide-loading, and saline-loading tests, indicated autonomous aldosterone secretion (Supplemental Table 1), confirming initial diagnosis.

Because the patient and her family preferred tumorectomy to medication, we attempted to localize the putative adenoma by imaging evaluation and selective adrenal venous sampling. We could not detect adenoma by computed tomography and magnetic resonance imaging of the adrenal glands. Selective adrenal venous sampling showed that PAC of the left vein after ACTH stimulation (3630 ng/dL) was significantly higher than the cutoff level for APA (PAC \> 1400 ng/dL), whereas serum cortisol level of the right vein after ACTH stimulation was not elevated enough (Supplemental Table 2) \[[@B2]\]. We then proceeded with laparoscopic left adrenalectomy. Macroscopically, the tumor was well circumscribed, and the size was 20 × 15 × 8 mm (Supplemental Fig. 1). Histopathologic examination showed that the tumor was a well-defined adrenocortical adenoma consisting of bright clear cells that were not typical for fasciculata or glomerulosa cells ([Fig. 1](#F1){ref-type="fig"}). After adrenalectomy, her blood pressure and serum potassium levels were 110/76 mm Hg and 4.4 mEq/L, respectively.

![Histopathology of APA in lower-magnification (×2.5) and higher-magnification (×20) views. (a, b) Hematoxylin-eosin (HE) staining indicates a well-defined nodule with bright clear cells in the left adrenal gland. (c-f) Immunohistochemical staining detected strong immunoreactivity for CYP11B2, but not for CYP11B1, in the APA. Positive immunoreactivities are shown in brown.](js-01-1056-f1){#F1}

We performed immunohistochemical staining using rabbit polyclonal antihuman CYP11B1 antibodies (5000-fold dilution) \[[@B6]\] and mouse monoclonal antihuman CYP11B2 antibody (10-fold dilution of hybridoma supernatant) that was produced by using a peptide corresponding to the amino acid residues from 41 to 52 as an antigen \[[@B7]\]. Immunohistochemistry detected strong immunoreactivity for CYP11B2, but not for CYP11B1 in the APA, compared with the residual adrenal cortex ([Fig. 1](#F1){ref-type="fig"}).

We obtained written informed consent from the patient\'s parents to perform molecular studies, which were approved by the Ethics Committee of the Keio University School of Medicine. We extracted genomic DNA from peripheral lymphocytes and APA cells isolated from paraffin sections using laser-capture microdissection (PALM MicroBeam; Carl Zeiss MicroImaging GmBH, Jena, Germany). We analyzed *KCNJ5* in these two genomic DNA samples by polymerase chain reaction--based sequencing. The primers are shown in Supplemental Table 3. We detected a previously reported mutation \[[@B4]\], c.503T\>G, p.L168R, in APA cells but not in peripheral lymphocytes ([Fig. 2](#F2){ref-type="fig"}), indicating the presence of a somatic *KCNJ5* mutation in APA cells.

![Chromatographs of Sanger sequencing of *KCNJ5*. (a) p.L168R was identified in genomic DNA extracted from aldosterone-producing adenoma. The heterozygous substitution of leucine by arginine is indicated by an arrow. (b) The genotype of genomic DNA from the patient\'s peripheral lymphocytes was wild-type.](js-01-1056-f2){#F2}

2. Discussion {#s2}
=============

We report an 11-year-old girl with APA who presented with recurrent headaches and nausea. She was not diagnosed with APA until severe hypertension and hypokalemia were evident. We identified a somatic *KCNJ5* mutation in the APA cells.

To our knowledge, there has been no previously reported case of pediatric-onset APA with a somatic *KCNJ5* mutation detected in APA cells using laser-capture microdissection. Somatic *KCNJ5* mutations were previously identified in 65% to 69% of Japanese patients with adult-onset APA, most frequently in the fifth decade of life \[[@B5]\]. Whether somatic *KCNJ5* mutations are sufficient for development of APA is still not clear. Taking into account that the patient already had symptoms that suggested the presence of APA at 9 years of age, we believe that the somatic *KCNJ5* mutation could be associated with pediatric-onset APA. Further studies are required to understand whether somatic *KCNJ5* mutations are a major genetic contributing factor in pediatric-onset APA.

Functional and morphologic characteristics of APA with a somatic *KCNJ5* mutation are not fully understood. Monticone *et al.* \[[@B8]\] reported that *KCNJ5*-mutated APAs in Italy were composed mainly of fasciculata-like cells with higher CYP11B1 and lower CYP11B2 expressions than those in APAs of other causes. Okamura *et al.* \[[@B9]\] found that *KCNJ5*-mutated APAs in Japan had higher *CYP11B2* and lower *CYP11B1* mRNA levels than those without mutation. The APA in our patient expressed abundant CYP11B2 and scarce CYP11B1. We speculate that the combination of abundant CYP11B2 and scarce CYP11B1 can be characteristic for pediatric-onset or Japanese APA with a somatic *KCNJ5* mutation.

Our patient was diagnosed with PA more than 2 years after her first visit for headache and nausea. We reviewed previously reported cases of pediatric-onset APA and cases of FH type III due to germline *KCNJ5* mutations in patients younger than age 15 years ([Tables 1 and 2](#T1){ref-type="table"}[](#T2){ref-type="table"}). Blood pressure at the first visit for medical attention was not reported in eight patients with APA and five with FH type III (patients 1, 3, 7, 9, 11, 12, 19, 23, 24, 31, and 41 to 43) (Supplemental references 1, 3, 7, 9, 11, 12, 19, 23--27, 32--34). One patient with APA (patient 5) showed mild hypertension but was not evaluated in the next 2 years (Supplemental reference 5). It is important to stress the importance of blood pressure measurement in children who experience headaches or symptoms associated with hypokalemia. Wyszyńska *et al.* \[[@B10]\] reported that hypertension in children is secondary to a known disease in 98% of cases. Therefore, children with hypertension should be further evaluated to reveal possible underlying causes.

###### 

**Clinical Features of Pediatric-Onset APA**

  Patient     Age at Onset, y   Age at Diagnosis, y   Blood Pressure, mm Hg   PRA , ng/mL per h   PAC, pmol/L   Potassium, mEq/L   Initial Symptoms                  Supplemental Reference
  ----------- ----------------- --------------------- ----------------------- ------------------- ------------- ------------------ --------------------------------- ------------------------
  1           1                 3                     160/110                 NA                  NA            2.4                P                                 1
  2           6                 7                     150/106                 \<0.1               NA            4.1                E, behavioral change, back pain   2
  3           7                 10                    200/100                 0.07                28,530        1.4                E, P                              3
  4           NA                8                     150/120                 \<0.2               1108          2.2                Asymptomatic                      4
  5           7                 9                     130/90                  NA                  NA            2.0                P                                 5
  6           7                 7                     140/100                 \<0.2               693           3.3                H                                 6
  7           7                 10                    125/100                 0.04                1222          2.5                E, P                              7
  8           NA                10                    170/130                 0.02                604           3.5                Asymptomatic                      8
  9           3                 5                     160/104                 \<0.15              1235          1.4                M, P                              9
  10          9                 9                     160/110                 0.08                1665          1.2                E, M, P                           10
  11          7                 10                    180/120                 \<0.2               1711          2.3                H                                 11
  12          9                 11                    170/110                 0.18                1040          2.2                H                                 12
  13          10                11                    180/120                 0.3                 1320          1.9                D, H, tinnitus                    13
  14          1                 10                    130/100                 0.6                 NA            2.8                H, M, P                           14
  15          10                11                    230/126                 \<0.3               1260          1.9                D, H, tinnitus                    15
  16          4                 5                     150/80                  0.1                 3047          1.5                D, M, P                           16
  17          0                 0                     137/97                  0.5                 \>4100        3.1                Asymptomatic                      17
  18          11                11                    140/96                  NA                  2216          2.4                M, palpitation, paresthesia       18
  19          6                 8                     130/90                  3.59                1025          2.9                H, paresthesia                    19
  20          12                12                    200/115                 \<0.2               475           4.2                D                                 20
  21          13                13                    140/100                 \<0.2               1385          2.0                M                                 21
  22          9                 10                    170/100                 0.1                 1160          \<1.5              H, P, palpitation                 22
  23          13                15                    150/100                 3.9                 2789          2.3                H                                 23
  This case   9                 11                    149/105                 \<0.1               792           2.7                H, nausea                         ---

Abbreviations: D, dizziness; E, enuresis; H, headache; M, muscular weakness; NA, not available; P, polyuria and polydipsia; PRA, plasma renin activity.

###### 

**Clinical Features of FH Type III**

  Patient   *KCNJ5* Genotype   Age at Onset, y   Age at Diagnosis, y   Blood Pressure, mm Hg   PRA , ng/mL per h   PAC, pmol/L   Potassium, mEq/L   Initial Symptoms       Supplemental Reference
  --------- ------------------ ----------------- --------------------- ----------------------- ------------------- ------------- ------------------ ---------------------- ------------------------
  24        p.T158A            3                 5                     230/140                 NA                  NA            2.8                H, P                   24, 25
  25        p.T158A            NA                7                     188/140                 0.3                 3805          1.8                NA                     25
  26        p.T158A            NA                4                     148/114                 0.2                 5127          1.9                NA                     25
  27        p.G151R            NA                1                     174/85                  \<0.2               NA            2.1                Muscular weakness      26
  28        p.G151R            NA                1                     120/70                  0.1                 NA            1.4                NA                     26
  29        p.G151R            NA                1                     130/90                  \<0.2               2440          3.2                P, failure to thrive   26
  30        p.G151R            NA                4                     127/80                  \<0.1               638           1.7                NA                     26
  31        p.G151E            NA                11                    160/120                 NA                  NA            3.0                P                      26, 27
  32        p.G151E            NA                2                     135/85                  \<0.1               NA            3.5                Asymptomatic           26, 28
  33        p.G151E            NA                1                     153/94                  \<0.1               2520          2.6                NA                     26
  34        p.G151E            NA                0                     130/NA                  \<0.1               8230          4.4                NA                     26
  35        p.G151E            NA                4                     NA                      \<0.1               NA            NA                 NA                     26
  36        p.G151E            NA                \<6                   NA                      NA                  NA            NA                 NA                     26
  37        p.I157S            NA                2                     150/100                 0.22                3269          2.7                NA                     29
  38        p.I157S            NA                7                     170/100                 \<0.1               NA            NA                 NA                     29
  39        p.G151E            2                 2                     130/80                  0.1                 3130          2.8                P                      30, 31
  40        p.G151E            \<10              24                    190/115                 0.5                 1479          2.9                P                      30, 31
  41        p.Y152C            48                62                    180/110                 \<0.6               665           2.1                H, nausea              32
  42        p.G151R            1                 4                     130/90                  0.1                 641           3.1                P                      33
  43        p.E145Q            0                 2                     115/65                  0.2                 \>5000        2.3                P, failure to thrive   34

Abbreviations: H, headache; NA, not available; P, polyuria and polydipsia; PRA, plasma renin activity.

According to the clinical features of pediatric-onset APA, the initial symptoms of pediatric-onset APA were not specific and were similar to those of FH type III. In addition, onset ages between pediatric-onset APA (range, 0 to 13 years) and FH type III (range, 0 to 48 years) overlapped, even though patients with FH type III were diagnosed at a younger age than those with APA. Molecular analysis would help distinguish between APA and FH type III in pediatric-onset PA because imaging studies, including computed tomography and magnetic resonance imaging, are not always informative \[[@B2]\], and selective adrenal venous sampling is difficult for young children.

In conclusion, somatic *KCNJ5* mutations are associated with pediatric-onset APA as well as adult-onset APA. Further cases are needed to elucidate molecular, functional, and morphologic characteristics of pediatric-onset APA with a somatic *KCNJ5* mutation.

Abbreviations: ACTHadrenocorticotropic hormoneAPAaldosterone-producing adenomaFHfamilial hyperaldosteronismPAprimary aldosteronismPACplasma aldosterone concentration.

We thank Professor Takao Takahashi for insightful discussions and support.

This work was supported by the Grant-in-Aid for Scientific Research (C) (grant number 16K09996 to T.I., 15K10650 to K.N., and 17K09890 to K.M.) from the Japan Society for the Promotion of Science and the Mother and Child Health Foundation (to T.I.).

Disclosure Summary: The authors have nothing to disclose.
